| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Medicine (S.E., L.Z.), Laboratory Medicine and Pathobiology (S.L.A.), University of Toronto; The Freeman Centre for Endocrine Oncology (S.E., L.Z., S.L.A.), Mount Sinai Hospital; and Ontario Cancer Institute (S.E., L.Z., S.L.A.), University Health Network, Toronto, Ontario, Canada M5G-1X5
Address all correspondence and requests for reprints to: Dr. S. Asa, 610 University Avenue, 4-302, Toronto, Ontario, Canada M5G-2M9. E-mail: sylvia.asa{at}uhn.on.ca.
We previously identified pituitary tumor-derived fibroblast growth factor receptor 4 (ptd-FGFR4), an alternatively transcribed N-terminally truncated cytoplasmic receptor isoform. Unlike wild-type FGFR4, ptd-FGFR4 facilitates cell transformation and results in pituitary tumor formation in transgenic mice. To investigate differences in the tumorigenic properties of FGFR4 and ptd-FGFR4, we examined their abilities to modulate cell adhesiveness. Introduction of ptd-FGFR4 into GH4 pituitary cells or NIH 3T3 fibroblasts resulted in significant reduction in cell adhesion to a collagen IV matrix compared with FGFR4- or empty vector-transfected cells. This adhesive difference was evident in the absence or presence of FGF stimulation. Furthermore, treatment with ß1-integrin neutralizing antibody markedly reduced adhesiveness in FGFR4-transfected cells but had little effect on the depressed adhesiveness of ptd-FGFR4-transfected cells. Unlike wild-type FGFR4, ptd-FGFR4 does not associate with neural cell-adhesion molecule (NCAM). Cells expressing FGFR4 demonstrate membranous N-cadherin with a noninvasive growth pattern identical to control GH4 cells when injected into immunodeficient mice. In contrast, ptd-FGFR4-expressing cells develop invasive tumors in vivo with marked loss of N-cadherin that localizes to the cytoplasm. Consistent with these changes, ß-catenin expression was diminished and its interaction with N-cadherin was disrupted in the presence of ptd-FGFR4, but both were intact in the presence of wild-type FGFR4. These data highlight the importance of membrane-anchored FGFR4 in assembling a multiprotein FGFR4 complex with NCAM and N-cadherin playing pivotal functions in maintaining normal cell adhesion. Disruption of distinct NCAM/N-cadherin proadhesive complexes by a tumor-derived FGFR4 isoform provides a novel mechanism beyond ligand independence that explains the pathobiology of proliferative and infiltrative but nonmetastatic neoplasms.
This article has been cited by other articles:
 |
|
 |
|
  M. Xu, L. Shorts-Cary, A. J. Knox, B Kleinsmidt-DeMasters, K. Lillehei, and M. E. Wierman Epidermal Growth Factor Receptor Pathway Substrate 8 Is Overexpressed in Human Pituitary Tumors: Role in Proliferation and Survival Endocrinology, May 1, 2009; 150(5): 2064 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhu, S. L. Asa, and S. Ezzat Fibroblast Growth Factor 2 and Estrogen Control the Balance of Histone 3 Modifications Targeting MAGE-A3 in Pituitary Neoplasia Clin. Cancer Res., April 1, 2008; 14(7): 1984 - 1996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cristina, G. Diaz-Torga, A. Gongora, M. C. Guida, M. I. Perez-Millan, A. Baldi, and D. Becu-Villalobos Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1341 - E1351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhu, K. Lee, S. L. Asa, and S. Ezzat Epigenetic Silencing through DNA and Histone Methylation of Fibroblast Growth Factor Receptor 2 in Neoplastic Pituitary Cells Am. J. Pathol., May 1, 2007; 170(5): 1618 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Boikos and C. A. Stratakis Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis Hum. Mol. Genet., April 15, 2007; 16(R1): R80 - R87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Shorts-Cary, M. Xu, J. Ertel, B. K. Kleinschmidt-Demasters, K. Lillehei, I. Matsuoka, S. Nielsen-Preiss, and M. E. Wierman Bone Morphogenetic Protein and Retinoic Acid-Inducible Neural Specific Protein-3 Is Expressed in Gonadotrope Cell Pituitary Adenomas and Induces Proliferation, Migration, and Invasion Endocrinology, March 1, 2007; 148(3): 967 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ezzat, L. Zheng, D. Winer, and S. L. Asa Targeting N-Cadherin through Fibroblast Growth Factor Receptor-4: Distinct Pathogenetic and Therapeutic Implications Mol. Endocrinol., November 1, 2006; 20(11): 2965 - 2975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ezzat, X. Zhu, S. Loeper, S. Fischer, and S. L. Asa Tumor-Derived Ikaros 6 Acetylates the Bcl-XL Promoter to Up-Regulate a Survival Signal in Pituitary Cells Mol. Endocrinol., November 1, 2006; 20(11): 2976 - 2986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Ezzat and S L Asa The molecular pathogenetic role of cell adhesion in endocrine neoplasia J. Clin. Pathol., November 1, 2005; 58(11): 1121 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ezzat, S. Yu, and S. L. Asa The Zinc Finger Ikaros Transcription Factor Regulates Pituitary Growth Hormone and Prolactin Gene Expression through Distinct Effects on Chromatin Accessibility Mol. Endocrinol., April 1, 2005; 19(4): 1004 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ezzat, P. Huang, A. Dackiw, and S. L. Asa Dual Inhibition of RET and FGFR4 Restrains Medullary Thyroid Cancer Cell Growth Clin. Cancer Res., February 1, 2005; 11(3): 1336 - 1341. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
